Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease.
Biopharmaceutical Company Publishes Positive Data For Crohn's Disease Treatment
Biopharmaceutical Company Publishes Positive…
Biopharmaceutical Company Publishes Positive Data For Crohn's Disease Treatment
Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease.